Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: A double-blind, randomized, vehicle-controlled study

Cutis

Volumn 77, Issue 1, 2006, Pages 45-50

  Grimes, Pearl ^a   Callender, Valerie ^b  

^a Vitiligo and Pigmentation Institute of Southern California   (United States)

^b Callender Skin and Laser Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; NICOTINIC ACID DERIVATIVE; TAZAROTENE;

ACNE VULGARIS; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERPIGMENTATION; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPIGMENTATION; MALE; MIDDLE AGED; NICOTINIC ACIDS; TREATMENT OUTCOME;

EID: 31944436395     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Laude TA. Skin disorders in black children. Curr Opin Pediatr. 1996;8:381-385.
2. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975;111:40-48.
3. Taylor SC. Cosmetic problems in skin of color. Skin Pharmacol Appl Skin Physiol. 1999;12:139-143.
4. Kenney JA. Dermatoses common in blacks. Postgrad Med. 1977;61:122-127.
5. Burns RL, Prevost-Blank PL, Lawry MA, et al. Glycolic acid peels for postinflammatory hyperpigmentation in black patients. a comparative study. Dermatol Surg. 1997;23: 171-175.
6. Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol. 1994;20: 592-597.
7. Bulengo-Ransby SM, Griffiths C, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328:1438-1443.
8. Yoshimura K, Harii K, Aoyama T, et al. Experience with a strong bleaching treatment for skin hyperpigmentation in Orientals. Plast Reconstr Surg. 2000;105:1097-1110.
9. Jacyk WK. Adapalene in the treatment of African patients. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):37-42.
10. Taylor S. Tazarotene in the treatment of pseudofolliculitis barbae in patients with skin of color: an investigator-masked, split-face, placebo-controlled, parallel-group study. Poster presented at: American Academy of Dermatology Summer Meeting; July 31-August 4, 2002; New York, NY. P26.
11. Phillips TJ, Gottlieb AB, Leyden JJ, et al, and the Tazarotene Cream Photodamage Clinical Study Group. Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial. Arch Dermatol. 2002;138:1486-1493.
12. Kang S, Leyden JJ, Lowe NJ, et al. Tazarotene cream for the treatment of facial photodamage. Arch Dermatol. 2001;137:1597-1604.
13. Tsuchiya AM. Tazarotene in the management of epidermal nevi. Poster presented at: 60th Annual Meeting of the American Academy of Dermatology; February 22-27, 2002; New Orleans, La. P190.
14. Weisshaar E, Bonnekoh B, Franke I, et al. Successful symptomatic tazarotene treatment of juvenile acanthosis nigricans of the familial obesity-associated type in insulin resistance. Hautarzt. 2001;52:499-503.
15. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis. 1999;63:349-354.
16. Shalita AR, Berson DS, Thiboutot DM, et al. Tazarotene cream in the treatment of acne, two multicenter, double-blind, randomized, vehicle-controlled, parallel-group studies of the safety and efficacy of tazarotene cream 0.1% applied once daily for 12 weeks in patients with acne vulgaris. Poster presented at: American Academy of Dermatology Summer Meeting; July 28-August 1, 2001; Anaheim, Ca. P05.
17. Grimes PE. Using tazarotene to treat acne in patients with skin type V or VI. Poster presented at: 60th Annual Meeting of the American Academy of Dermatology; February 22-27, 2002; New Orleans, La. P47.